Neoadjuvant in Clinical Utility

Neoadjuvant therapy

For patients with large tumor to breast ratios who are interested in breast-conserving surgery, neoadjuvant therapy—such as chemotherapy or endocrine therapy—is an increasingly common consideration.

Research results have shown that the Breast Recurrence Score test is a predictor of response to neoadjuvant treatment and provides useful information to guide systemic treatment decisions:1-5

  • Neoadjuvant studies are consistent with adjuvant studies that the Recurrence Score results correlate with benefits from adjuvant hormonal therapy and chemotherapy.
  • Results indicate that lower Recurrence Score results are associated with greater clinical responses from neoadjuvant hormonal therapy.
  • Findings suggest that higher Recurrence Score results are associated with greater clinical and pathologic responses from neoadjuvant chemotherapy.
  • Download Research Results PDF

    REFERENCES

    1. Gianni et al. J Clin Oncol. 2005.
    2. Ueno et al. Int J Clin Oncol. 2013.
    3. Yardley et al. Breast Cancer Res Treat. 2015.
    4. Bear et al. SABCS 2016.
    5. Robidoux et al. Miami Breast Cancer Conference 2017.

    a. DOI: 10.1056/NEJMoa1804710.

    *American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy

    Making cancer care smarter.®